CCHT(SZ:000661) Xin Lang Zheng Quan·2025-09-24 06:37Group 1 - The core viewpoint of the news is that Changchun High-tech has shown a significant stock performance with a year-to-date increase of 24.97%, despite a recent decline of 2.27% over the last five trading days [1] - As of September 24, the stock price reached 121.07 yuan per share, with a total market capitalization of 49.389 billion yuan [1] - The company has seen a net inflow of main funds amounting to 18.2718 million yuan, with large orders contributing significantly to the trading volume [1] Group 2 - Changchun High-tech's main business revenue composition is 92.83% from pharmaceuticals, 6.81% from real estate, and 0.36% from services [1] - As of June 30, the company reported a revenue of 6.603 billion yuan for the first half of 2025, reflecting a year-on-year decrease of 0.54%, while the net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - The company has distributed a total of 4.791 billion yuan in dividends since its A-share listing, with 3.259 billion yuan distributed in the last three years [3] Group 3 - As of June 30, 2025, the number of shareholders decreased by 12.78% to 109,100, while the average circulating shares per person increased by 14.66% to 3,662 shares [2] - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, holding 8.4381 million shares [3] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is associated with various investment concepts such as Northeast revitalization and high dividend stocks [2]